Tracer library / [68Ga]Ga-DOTA-r-a-ABA-CPCR4
[68Ga]Ga-DOTA-r-a-ABA-CPCR4
Also written as [68Ga]DOTA-r-a-ABA-CPCR4; [Ga-68]DOTA-r-a-ABA-CPCR4
- Radionuclide
- Ga-68 t½ 67.71 min
- Modality
- PET
- Production route
- —
- Stage
- Preclinical
- Syntheses indexed
- 1
What it is
- Compound class
- DOTA-conjugated cyclic pentapeptide CXCR4 ligand (CPCR4-based)
- Target / mechanism
- CXCR4 receptor ligand PMID 32724470
- Clinical application
- PET imaging of CXCR4 expression in cancer and inflammation (human B cell lymphoma xenograft model) PMID 32724470
- Theranostic pair
- [177Lu]Lu-DOTA-r-a-ABA-CPCR4
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | — | — | — | DOTA-r-a-ABA-CPCR4 | 32724470 2020 Theranostics All peptides and their respective natGa-, natLu-, natY- and natBi- complexes were synthesized in analogy to previously published protocols |
Need this precursor?We can point you to suppliers for [68Ga]Ga-DOTA-r-a-ABA-CPCR4, or handle the enquiry for you.
Get in touchQuality control Preliminary - inferred from compound class
- Ph. Eur. monograph
- not verified No Ph. Eur. check is recorded for this entry.
- USP monograph
- not verified No USP check is recorded for this entry.
How this set was arrived at. base set per Ph. Eur. general monograph 0125 (rule); radiometal tracer -> metal impurities (rule); Ga-68, generator production assumed (no synthesis data found) -> Ge-68 breakthrough (preliminary); receptor ligand with a saturable target -> molar activity (rule)
Tests listed by reference only. Monograph texts are copyrighted and are not reproduced here. How these are derived
Setting up quality control?We can help you scope the equipment needed to release [68Ga]Ga-DOTA-r-a-ABA-CPCR4.
Get in touchNotes
Added from reverse module search (stage 6); 1 article(s) with Ga-68. Also seen with Lu-177[1] (too few articles for own row). Compound class inferred from precursor name (not stated outright) -- PMID 32724470: 'DOTA-r-a-ABA-CPCR4 (entry 13)'. Stage set/updated at stage 23 from PMID 32724470: 'will be further evaluated in preclinical and clinical CXCR4-targeted dosimetry and RLT studies.'.